Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.62
CLSN's Cash to Debt is ranked higher than
65% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CLSN: 4.62 )
CLSN' s 10-Year Cash to Debt Range
Min: 0.45   Max: No Debt
Current: 4.62

Equity to Asset 0.53
CLSN's Equity to Asset is ranked higher than
64% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CLSN: 0.53 )
CLSN' s 10-Year Equity to Asset Range
Min: -1.05   Max: 0.97
Current: 0.53

-1.05
0.97
F-Score: 2
Z-Score: -3.13
M-Score: 15.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4309.40
CLSN's Operating margin (%) is ranked higher than
52% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -80.68 vs. CLSN: -4309.40 )
CLSN' s 10-Year Operating margin (%) Range
Min: -163200   Max: -75.32
Current: -4309.4

-163200
-75.32
Net-margin (%) -4597.60
CLSN's Net-margin (%) is ranked higher than
52% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CLSN: -4597.60 )
CLSN' s 10-Year Net-margin (%) Range
Min: -151566.67   Max: -67.41
Current: -4597.6

-151566.67
-67.41
ROE (%) -61.96
CLSN's ROE (%) is ranked higher than
64% of the 1124 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CLSN: -61.96 )
CLSN' s 10-Year ROE (%) Range
Min: -6771.43   Max: 257.55
Current: -61.96

-6771.43
257.55
ROA (%) -38.19
CLSN's ROA (%) is ranked higher than
69% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. CLSN: -38.19 )
CLSN' s 10-Year ROA (%) Range
Min: -727.9   Max: 121.96
Current: -38.19

-727.9
121.96
ROC (Joel Greenblatt) (%) -2436.34
CLSN's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. CLSN: -2436.34 )
CLSN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14838.71   Max: -114.68
Current: -2436.34

-14838.71
-114.68
EBITDA Growth (%) -57.50
CLSN's EBITDA Growth (%) is ranked higher than
51% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. CLSN: -57.50 )
CLSN' s 10-Year EBITDA Growth (%) Range
Min: -57.5   Max: 39.1
Current: -57.5

-57.5
39.1
EPS Growth (%) -48.20
CLSN's EPS Growth (%) is ranked higher than
55% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CLSN: -48.20 )
CLSN' s 10-Year EPS Growth (%) Range
Min: -48.2   Max: 30.5
Current: -48.2

-48.2
30.5
» CLSN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CLSN Guru Trades in Q4 2013

Jim Simons 48,307 sh (New)
Chuck Royce 35,555 sh (unchged)
» More
Q1 2014

CLSN Guru Trades in Q1 2014

Chuck Royce 233,159 sh (+555.77%)
Jim Simons Sold Out
» More
Q2 2014

CLSN Guru Trades in Q2 2014

Chuck Royce 233,159 sh (unchged)
» More
Q3 2014

CLSN Guru Trades in Q3 2014

Jim Simons 49,964 sh (New)
Chuck Royce 233,159 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.26
CLSN's P/B is ranked higher than
95% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. CLSN: 1.26 )
CLSN' s 10-Year P/B Range
Min: 1.25   Max: 30.16
Current: 1.26

1.25
30.16
P/S 89.11
CLSN's P/S is ranked higher than
71% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 32.77 vs. CLSN: 89.11 )
CLSN' s 10-Year P/S Range
Min: 1.81   Max: 2210.6
Current: 89.11

1.81
2210.6
EV-to-EBIT -0.66
CLSN's EV-to-EBIT is ranked higher than
75% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CLSN: -0.66 )
CLSN' s 10-Year EV-to-EBIT Range
Min: -11.6   Max: 0.3
Current: -0.66

-11.6
0.3
Current Ratio 4.73
CLSN's Current Ratio is ranked higher than
73% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. CLSN: 4.73 )
CLSN' s 10-Year Current Ratio Range
Min: 0.3   Max: 104.65
Current: 4.73

0.3
104.65
Quick Ratio 4.73
CLSN's Quick Ratio is ranked higher than
74% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CLSN: 4.73 )
CLSN' s 10-Year Quick Ratio Range
Min: 0.3   Max: 104.65
Current: 4.73

0.3
104.65

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.11
CLSN's Price/Net Cash is ranked higher than
89% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 105.66 vs. CLSN: 5.11 )
CLSN' s 10-Year Price/Net Cash Range
Min: 1.51   Max: 388.72
Current: 5.11

1.51
388.72
Price/Net Current Asset Value 5.00
CLSN's Price/Net Current Asset Value is ranked higher than
88% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 37.29 vs. CLSN: 5.00 )
CLSN' s 10-Year Price/Net Current Asset Value Range
Min: 1.5   Max: 388.72
Current: 5

1.5
388.72
Price/Tangible Book 1.32
CLSN's Price/Tangible Book is ranked higher than
97% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. CLSN: 1.32 )
CLSN' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 222.75
Current: 1.32

1.05
222.75
Price/Median PS Value 9.80
CLSN's Price/Median PS Value is ranked higher than
70% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. CLSN: 9.80 )
CLSN' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 334.8
Current: 9.8

0.3
334.8
Earnings Yield (Greenblatt) -151.50
CLSN's Earnings Yield (Greenblatt) is ranked lower than
53% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CLSN: -151.50 )
CLSN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 326.4   Max: 771.8
Current: -151.5

326.4
771.8
Forward Rate of Return (Yacktman) -99.39
CLSN's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. CLSN: -99.39 )
CLSN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -111.4   Max: 32.8
Current: -99.39

-111.4
32.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CBOB.Germany
Celsion Corp was founded in 1982 and is a Delaware corporation. It is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. The Company is working to develop and commercialize chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The Company's product ThermoDox(r) is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox(r) is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of various cancers. Localized heat at mild hyperthermia temperatures (greater than 40 degrees Celsius) releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. The Company is engaged in a limited amount of research and development in its own facilities and also sponsor research programs in partnership with various research institutions, including the National Cancer Institute and Duke University. Competition in the discovery and development of new methods for treating and preventing disease is intense. The Company face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to extensive regulation by the FDA and foreign regulatory agencies.
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Dead Biotech Plays Surge To Life May 07 2013 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Reports Second Quarter 2009 Financial Results and Business Update Aug 05 2009 
Celsion to Hold Second Quarter 2009 Financial Results Jul 31 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 
Celsion Corporation to Hold Conference Call to Discuss Its Announced Japan License Agreement for The Dec 16 2008 
Celsion Corporation Announces Exclusive Japan License Agreement with Yakult Honsha for ThermoDox® Dec 15 2008 

More From Other Websites
CELSION CORP Financials Nov 18 2014
10-Q for Celsion Corp. Nov 12 2014
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 12 2014
Celsion Corporation Reports Third Quarter 2014 Financial Results Nov 11 2014
Celsion Corporation Reports Third Quarter 2014 Financial Results Nov 11 2014
CELSION CORP Files SEC form 10-Q, Quarterly Report Nov 10 2014
Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe Nov 05 2014
Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe Nov 05 2014
Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday,... Nov 04 2014
Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday,... Nov 04 2014
Celsion Presents Preclinical Data for its TheraSilence™ Platform at the miRNA World Conference... Oct 29 2014
Celsion Presents Preclinical Data for its TheraSilence™ Platform at the miRNA World Conference... Oct 29 2014
CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 07 2014
Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors Oct 07 2014
Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board Oct 07 2014
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp.... Sep 17 2014
Celsion Announces Highlights from Three Presentations Given at the International Liver Cancer... Sep 08 2014
Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on... Sep 04 2014
Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in... Sep 02 2014
Celsion to Present at the Rodman & Renshaw 16th Annual Healthcare Conference Aug 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK